Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

This study is composed of two stages: Part A is a randomized, double-blind, placebo-controlled dose-escalation study (i.e., Phase 1b study). The first part has a total of 3 dose groups, with 10 subjects enrolled in each dose group. Subjects are randomly assigned to receive MIL62 combined with standard of care or placebo combined with standard of care at a 4:1 ratio. Based on the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary efficacy of the 3 dose groups, the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and dosing frequency will be determined.

Part B is open-label, enrolling 10 subjects who will receive the recommended dose of MIL62 combined with standard of care.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Lupus Nephritis Autoimmune Diseases Connective Tissue Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glomerulonephritis Immune System Diseases Kidney Diseases Lupus Erythematosus, Systemic Male Urogenital Diseases Nephritis Skin and Connective Tissue Diseases Urogenital Diseases Urologic Diseases

Age range

18 year–74 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Peking University People's Hospital

Beijing, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥18 years and <75 years, gender not restricted;
Diagnosed with systemic lupus erythematosus (SLE) according to the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria;
Urinary protein/creatinine ratio (UPCR) > 1.0 (24-hour urine);
If the patient is taking drugs that may affect kidney function (e.g., ACE inhibitors, cholesterol-lowering drugs), the dosage must remain stable for at least 4 weeks prior to enrollment and throughout the study;
No need to receive vaccination during the study or need vaccination only after at least 16 weeks following the last dose of study drug;
Signed written informed consent.

Exclusion criteria

Screening reveals other severe kidney diseases or conditions, including: ① Need for dialysis or transplant therapy; ② Kidney biopsy within the last 6 months shows more than 50% glomerulosclerosis;
Screening reveals the following diseases or conditions: ① Other autoimmune diseases besides SLE; ② Clinically significant bleeding risks, or conditions requiring plasma exchange, blood transfusion, or platelet transfusion;
Positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), with HBV DNA levels outside normal range; positive for HCV antibody and HCV RNA; positive for HIV serum reaction; positive for syphilis test;
Pregnant and breastfeeding women; for women of childbearing potential who have not undergone sterilization: unwilling to use appropriate contraception methods (e.g., oral contraceptives, intrauterine devices, or barrier methods with spermicide) during the treatment period and for at least 18 months after the last dose of study drug;
For men who have not undergone sterilization: unwilling to use barrier contraception during the study and for at least 18 months after the last dose of study drug, and unwilling to have their spouse use other contraception methods;
The investigator considers other situations not suitable for participation in the study.

Treatment and study plan

Recombinant Humanized Monoclonal Antibody MIL62 Injection

Drug

Phase 1b:

Intravenous infusion. Dose group 1 (500mg), dose group 2 (1000mg); administered on Day 1 of Weeks 1, 3, 25, 27, 53, 55, and 77. Dose group 3 (500mg), administered on Days 1, 2, 3, 4, 25, 26, 27, 28, 53, 54, 55, 56, 77, and 78 of each respective week.

Phase 2:

Use the dose and frequency determined in Phase 1b.

Placebo

Drug

Phase 1b:

Phase 2:

Use the dose and frequency determined in Phase 1b.

Primary outcomes

Percentage of subjects achieving complete renal remission (CRR) at 76 weeks

Time frame: week 76

Percentage of Participants with UPCR < 0.3 and estimated glomerular filtration rate (eGFR) decline ≤ 15% from baseline

Sponsors and collaborators

Lead sponsor

Beijing Mabworks Biotech Co., Ltd.

Industry

Registry information

Official study title

A Phase 1b/2 Clinical Study Evaluating the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in Subjects With Lupus Nephritis

Important dates

Study start: 2021
Primary completion: 2025
Study completion: 2025
First posted: Jun 29, 2025
Registry last updated: Jul 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting